Chelsie Derman

Patients with hidradenitis suppurativa had the greatest risk of developing various CVS, with heart failure being the most common one.

A study showed tildrakizumab treated difficult-to-treat psoriasis areas in patients who failed anti-IL17 treatment.

In an interview, King provided an overview of the history of psychedelic research for psychiatric conditions, where we are now, and what hurdles investigators must address.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

Phillips emphasizes the importance of screening for obsessive-compulsive disorders, such as OCD, body dysmorphic disorder, and trichillomania.

In an interview with HCPLive, Jha said clinicians should think of interventional approaches for treatment-resistant depression “sooner rather than later.”

In an interview, Phillip explained the difference between OCD and body dysmorphic disorder, even though they are grouped in the DSM-5.

In an interview with HCPLive, Barnett discussed the ethical concerns of using psychedelics for treating substance use disorders.

In an interview with Adler at APA 2024, he also explained how adults with ADHD may present additional symptoms not noted on the DSM when they have comorbidities.

In an interview with HCPLive, Karlin and Robinson discuss the phase 2b trial on MM120 for generalized anxiety disorder.

In an interview with HCPLive, Karlin discussed the unmet need for GAD screening.

At APA 2024, HCPLive interviewed APA members about how DSM-5-TR classifies psychiatric disorders differently than previous iterations.

In an interview, Paul Appelbaum, MD, discussed issues clinicians will need to bring up to their patients if the FDA approves a psychedelic-assisted therapy.

In an interview, Ryan McLaughlin discussed the ethical concerns regarding treating psychiatric illness with cannabis.

In an interview with Andrew Chen, MD, he explained why patients might need to turn to more adverse event prone anxiety medications.

In an interview with Andrew Chen, MD, he discussed the first-line treatment for generalized anxiety disorder and when to take other alterative medication.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.

This month in review features top psychiatry news in the pipeline, FDA approvals, and a piece for autism awareness month.

The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.

In an interview, Larry Ereshefsky, PharmD, discussed other conditions brilaroxazine could potentially treat other than schizophrenia due to its mechanism.

Many parents experience high levels of isolation, loneliness, and burnout, feeling like there is no one to talk to about their struggles in their daily lives.

Larry Ereshefsky, PharmD, discussed the effects of brilaroxazine on inflammatory cytokines and neuroinflammation and how this can impact future schizophrenia treatment.

FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.

The extent of stigma significantly differs based on disease visibility and severity among children with chronic skin disorders.

The fracture risk is greater for nursing home residents with dementia, greater baseline blood pressure values, and no recent antihypertensive medication use, a new study found.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.